Increased Lipoprotein (a) concentrations in patients with chronic venous leg ulcers: A study on patients with or without postthrombotic syndrome

Wound Repair and Regeneration

Volumn 19, Issue 2, 2011, Pages 168-172

  Zutt, Markus ^a   Krüger, Ulrich ^a   Rosenberger, Albert ^b   Schön, Michael P ^a   Neumann, Christine ^a   Von Ahsen, Nico ^a   Kretschmer, Lutz ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Medical School   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; LEG ULCER; MAJOR CLINICAL STUDY; MALE; POSTTHROMBOSIS SYNDROME; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SERUM; THROMBOSIS; ULCER; VEIN INSUFFICIENCY;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; POSTTHROMBOTIC SYNDROME; VARICOSE ULCER;

EID: 79952266276     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2010.00657.x     Document Type: Article

References (34)

1. Prandoni P, Kahn SR., Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009; 145: 286-95.
2. Kahn SR., How I treat postthrombotic syndrome. Blood 2009; 114: 4624-31.
3. Bradbury AW, MacKenzie RK, Burns P, Fegan C., Thrombophilia and chronic venous ulceration. Eur J Vasc Endovasc Surg 2002; 24: 97-104. (Pubitemid 41079363)
4. Gaber Y, Siemens HJ, Schmeller W., Increased prevalence of APC-resistance (factor V Leiden mutation) in patients with postthrombotic syndrome. Hautarzt 2000; 51: 590-2. (Pubitemid 30629227)
5. Gaber Y, Siemens HJ, Schmeller W., Resistance to activated protein C due to factor V Leiden mutation: high prevalence in patients with post-thrombotic leg ulcers. Br J Dermatol 2001; 144: 546-8. (Pubitemid 32232009)
6. Mackenzie RK, Ludlam CA, Ruckley CV, Allan PL, Burns P, Bradbury AW., The prevalence of thrombophilia in patients with chronic venous leg ulceration. J Vasc Surg 2002; 35: 718-22.
7. Munkvad S, JÃrgensen M., Antithrombin-III plasma levels in patients with venous leg ulcer disease. Acta Derm Venereol 1995; 75: 251.
8. Munkvad S, JÃrgensen M., Resistance to activated protein C: a common anticoagulant deficiency in patients with venous leg ulceration. Br J Dermatol 1996; 134: 296-8. (Pubitemid 26053587)
9. Darvall KA, Sam RC, Adam DJ, Silverman SH, Fegan CD, Bradbury AW., Higher prevalence of thrombophilia in patients with varicose veins and venous ulcers than controls. J Vasc Surg 2009; 49: 1235-41.
10. Berg K, Dahlen G, Borresen AL., Lp(a) phenotypes, other lipoprotein parameters, and a family history of coronary heart disease in middle-aged males. Clin Genet 1979; 16: 347-52. (Pubitemid 10214662)
11. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, Huttunen JK., Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.
12. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H., Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ 1990; 301: 1248-51.
13. Scanu AM., Lipoprotein(a). A genetic risk factor for premature coronary heart disease. JAMA 1992; 267: 3326-9.
14. Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PW, Castelli WP, Ordovas JM, Schaefer EJ., Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem 1999; 45: 1039-46. (Pubitemid 29340541)
15. Stein JH, Rosenson RS., Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997; 157: 1170-6. (Pubitemid 27251643)
16. Stiel GM, Reblin T, Buhrlen M, Lattermann A, Nienaber CA., Differences in lipoprotein (a) and apolipoprotein (a) levels in men and women with advanced coronary atherosclerosis. Coron Artery Dis 1995; 6: 347-50.
17. Jovicic A, Ivanisevic V, Ivanovic I., Lipoprotein(a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis 1993; 98: 59-65. (Pubitemid 23010424)
18. Jürgens G, Taddei-Peters WC, Költringer P, Petek W, Chen Q, Greilberger J, Macomber PF, Butman BT, Stead AG, Ransom JH., Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995; 26: 1841-8.
19. Nagayama M, Shinohara Y, Nagayama T., Lipoprotein(a) and ischemic cerebrovascular disease in young adults. Stroke 1994; 25: 74-8.
20. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu Lebdeh HS., Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997; 96: 1390-7. (Pubitemid 27375327)
21. Atsumi T, Khamashta MA, Andujar C, Leandro MJ, Amengual O, Ames PR, Hughes GR., Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol 1998; 25: 69-73. (Pubitemid 28060120)
22. Hervio L, Durlach V, Girard Globa A, Angles Cano E., Multiple binding with identical linkage: a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry 1995; 34: 13353-8.
23. Nowak-Göttl U, Junker R, Hartmeier M, Koch HG, Münchow N, Assmann G, von Eckardstein A., Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999; 100: 743-8. (Pubitemid 29383645)
24. von Depka M, Nowak-Göttl U, Eisert R, Dieterich C, Barthels M, Scharrer I, Ganser A, Ehrenforth S., Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96: 3364-8.
25. Marcucci R, Liotta AA, Cellai AP, Rogolino A, Gori AM, Giusti B, Poli D, Fedi S, Abbate R, Prisco D., Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med 2003; 115: 601-5. (Pubitemid 37505900)
26. Sofi F, Marcucci R, Abbate R, Gensini GF, Prisco D., Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med 2007; 120: 728-33. (Pubitemid 47189658)
27. Kistner RL, Eklof B, Masuda EM., Diagnosis of chronic venous disease of the lower extremities: the "CEAP" classification. Mayo Clin Proc 1996; 71: 338-45.
28. Kostner GM, Avogaro P, Cazzoloato G, Marth E, Bittolo-Bon G, Qunici GB., Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981; 38: 51-61. (Pubitemid 11138606)
29. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB., Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353: 46-57. (Pubitemid 41007806)
30. Falcõ C, Tormo G, Estellés A, España F, Tormo E, Gilabert J, Velasco JA, Aznar J., Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy. Haematologica 2001; 86: 92-8. (Pubitemid 32147057)
31. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M., Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78: 145-50. (Pubitemid 19195484)
32. Min WK, Lee JO, Huh JW., Relation between lipoprotein(a) concentrations in patients with acute-phase response and risk analysis for coronary heart disease. Clin Chem 1997; 43: 1891-5. (Pubitemid 27452278)
33. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U., Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989; 9: 579-92. (Pubitemid 19236892)
34. Trent JT, Falabella A, Eaglstein WH, Kirsner R., Venous ulcers: pathophysiology and treatment options. Ostomy Wound Manage 2005; 51: 38-54.